Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RA7mhc4MT3KfQGlqJU9SY5Un2rzpbaruWxKZmXDf-bTUI#assertion>. }

• association type Statement assertion.
• association label "seizure disorders clonazepam tablets usp are useful alone or as an adjunct in the treatment of the lennox gastaut syndrome petit mal variant akinetic and myoclonic seizures in patients with absence seizures petit mal who have failed to respond to succinimides clonazepam tablets usp may be useful in some studies up to 3 of patients have shown a loss of anticonvulsant activity often within 3 months of administration in some cases dosage adjustment may reestablish efficacy panic disorder clonazepam tablts usp are indicated for the treatment of panic disorder with or without agoraphobia as defined in dsm iv panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks worry about the implications or consequences of the attacks and or a significant change in behavior related to the attacks the efficacy of clonazepam tablets usp was established in two 6 to 9 week trials in panic disorder patients whose diagnoses corresponded to the dsm iiir category of panic disorder see clinical pharmacology clinical trials panic disorder dsm iv is characterized by recurrent unexpected panic attacks i e a discrete period of intense fear or discomfort in which four or more of the following symptoms develop abruptly and reach a peak within 1 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 1 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushes the effectiveness of clonazepam tablets usp in long term use that is for more than 9 weeks has not been systematically studied in controlled clinical trials the physician who elects to use clonazepam tablets usp for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient see dosage and administration" assertion.
• association object DOID_594 assertion.
• association predicate treats assertion.
• drugbank:DB01068 category Drug assertion.
• DOID_594 category Disease assertion.
• association subject drugbank:DB01068 assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
• association provided_by NeuroDKG assertion.
• association relation TreatmentIndication assertion.